

PRECEPTORSHIP PROGRAMME

Colorectal Cancer

Multidisciplinary management, standards
of care and future perspectives

VALENCIA
SPAIN

17-18 MAY 2019

Co-Chairs

Andrés Cervantes, ES
Dirk Arnold, PT

ESMO PRECEPTORSHIP PROGRAMME COLORECTAL CANCER

Multidisciplinary management, standards of care
and future perspectives

Valencia, Spain
17-18 May 2019

CO-CHAIRS: Andrés Cervantes, Spain
Dirk Arnold, Portugal

SPEAKERS: Regina Beets-Tan, Netherlands
Frédéric Bibeau, France
Chiara Cremolini, Italy
Dimitri Dorcaratto, Spain
Michel Ducreux, France
Demetris Papamichael, Cyprus
Francesco Sclafani, Belgium
Elizabeth Smyth, United Kingdom
Carlos Vaz, Portugal

LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology and histoprognostic factors
- To learn about the management of patients after progression, side-effects of treatments and in special situations

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 17 May 2019

09:00-09:15 15'	Welcome and introduction	Andrés Cervantes, ES Dirk Arnold, PT
09:15-10:35 80'	SESSION 1 Early colorectal cancer	Chair: Francesco Sclafani, BE
20'	The point of view of the pathologist: - Quality and rules of a good pathology report - Histo-prognostic factors: Number of lymph nodes, neural/lymphatic invasion, lymphocytic infiltration, MSH expression	Frédéric Bibeau, FR
20'	Optimal loco-regional staging for rectal cancer	Regina Beets-Tan, NL
20'	State-of-the-art: Standard(s) of surgical practice for resectable colorectal cancer (special issues on rectal cancer, laparoscopy, transanal TME and robotic-assisted surgery)	Carlos Vaz, PT
20'	State-of-the-art: Standard(s) of care in pre-operative treatment for rectal cancer	Francesco Sclafani, BE
10:35-11:05	Coffee break	
11:05-13:15 130'	SESSION 2 Adjuvant settings of colorectal cancer	Chair: Dirk Arnold, PT
30'	RAS, BRAF: Microsatellite instability and other molecular markers – How useful are they? Pitfalls in diagnostic?	Frédéric Bibeau, FR
30'	Adjuvant treatment for colon cancer II and III	Michel Ducreux, FR
20'	The role of chemotherapy of localized rectal cancer	Andrés Cervantes, ES
30'	Adjuvant treatment for elderly patients: How to address it	Demetris Papamichael, CY
10'	Participants clinical case discussion (1x10')	Faculty
13:15-14:15	Lunch	
14:15-16:10 115'	SESSION 3 Metastatic colorectal cancer: Liver limited metastases	Chair: Andrés Cervantes, ES
20'	Review of the ESMO Consensus Conference on metastatic colorectal cancer: Basic strategies and groups (RASwt/mut, BRAF mut)	Chiara Cremolini, IT
20'	Chemotherapy and targeted agents in first-line	Chiara Cremolini, IT
30'	Oligometastatic colorectal cancer: What to know about and how to treat it	Dirk Arnold, PT
45'	Presentation of three challenging clinical cases and faculty discussion	Andrés Cervantes, ES Faculty
16:10-16:40	Coffee break	

16:40-18:35 115'	SESSION 4 Metastatic colorectal cancer: Special clinical situations	Chair: Andrés Cervantes, ES
20'	How to integrate surgery in the treatment of patients with liver-only metastatic disease	Dimitri Dorcaratto, ES
15'	How to deal with elderly patients or individuals with comorbidities	Demetris Papamichael, CY
15'	How to deal with synchronous primary and liver metastases	Dimitri Dorcaratto, ES
15'	How to deal with patients with isolated peritoneal metastases	Michel Ducreux, FR
50'	Participants clinical case discussion (5x10')	Faculty
20:30	Dinner	

Saturday, 18 May 2019

08:30-10:00 90'	SESSION 5 Metastatic colorectal cancer: Maintenance and further lines	Chair: Dirk Arnold, PT
30'	The role of maintenance treatment, appropriate endpoints according to ESMO Consensus	Dirk Arnold, PT
30'	What to do after first-line failure	Dirk Arnold, PT
30'	Management of treatment-related side effects: <ul style="list-style-type: none"> - GI-toxicity - Neuropathy - Skin toxicity - Hypertension - Hand-foot syndrome 	Michel Ducreux, FR
10:00-10:30	Coffee break	
10:30-11:00 30'	SPECIAL LECTURE Immunotherapy in gastrointestinal cancers	Chair: Dirk Arnold, PT
30'	Immunotherapy in gastrointestinal cancers	Elizabeth Smyth, UK
11:00-11:20 20'	SESSION 6 Anal canal tumours	Chair: Francesco Sclafani, BE
20'	Standard of care for anal canal squamous carcinomas	Francesco Sclafani, BE
11:20-11:50 30'	SESSION 7 Metastatic colorectal cancer: Case discussion	Chair: Andrés Cervantes, ES
30'	Participants clinical case discussion (3x10')	Faculty
11:50-12:05 15'	Conclusion and farewell	Andrés Cervantes, ES Dirk Arnold, PT
12:05-13:00	Lunch	

Note: Each 10 minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion